中国药理学通报2017，Vol.33Issue(7)：896-899,4.DOI:10.3969/j.issn.1001-1978.2017.07.003
咪唑立宾治疗药物监测在肾移植术后患者中的应用进展
Therapeutic drug monitoring of mizoribine in renal transplant recipients
摘要
Abstract
Mizoribine(MZR), as an orally prescribed immunosuppressive agent, has been applied in the prevention of rejection after kidney transplantation.MZR requires individual dosing due to the variation of bioavailability.However, therapeutic drug monitoring (TDM) of MZR is not well developed in China, as compared to other clinically used immunosuppressive agents.To our knowledge, this is the first TDM review of MZR.Pharmacokinetic characteristic, concentration determination methods and sample selection of MZR were summarized, also the rational therapeutic window was proposed.Furthermore, gene polymorphism and population pharmacokinetics of MZR were estimated.This review will provide reference for TDM-based individual dosing of MZR in renal transplant recipients.关键词
咪唑立宾/治疗药物监测/肾移植/药动学/基因多态性/群体药动学/免疫抑制剂Key words
mizoribine/therapeutic drug monitoring/renal transplantation/pharmacokinetics/gene polymorphism/population pharmacokinetics/immunosuppressor分类
医药卫生引用本文复制引用
陈攀,傅茜,黄秋玲,李军,陈杰,陈孝,王长希,李晶洁..咪唑立宾治疗药物监测在肾移植术后患者中的应用进展[J].中国药理学通报,2017,33(7):896-899,4.基金项目
国家自然科学基金资助项目(No 81503156,81601347) （No 81503156,81601347）
广东省自然科学基金资助项目(No 2014A030310096) （No 2014A030310096）
广东省公益基金资助项目(No 2016A020218006) （No 2016A020218006）
